Since the loss of E-cadherin and transition into a mesenchymal state often characterize CSCs, a pharmacologically triggered MET was proposed as a potential therapeutic approach aiming to eliminate tumor-initiating cells41. The gene discussed is CDH1; the disease is neoplasm.